Don Berardinucci
Urology · Houston, TXNPI 1699774679
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,943 of the $3,594 with a category attached, or 81.9%. It is spread thinly across 30 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,199 and has fallen 72.3% since, to $332 in 2023. That places this record below the midpoint for urology clinicians in TX, where the typical reported total is $3,394.
Across 165 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$784
- Johnson & Johnson$467
- AbbVie$311
- Pfizer$266
- Boston Scientific$221
- Urovant Sciences Inc$214
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,94382%
- Education$65118%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 35 | $784 |
| Johnson & Johnson(2 entities) | 14 | $467 |
| AbbVie(2 entities) | 16 | $311 |
| Pfizer | 15 | $266 |
| Boston Scientific | 12 | $221 |
| Urovant Sciences Inc | 13 | $214 |
| Convatec Inc. | 8 | $192 |
| Coloplast | 4 | $160 |
| Endo Pharmaceuticals Inc. | 8 | $147 |
| Antares Pharma, Inc. | 8 | $122 |
| 180 Medical, Inc. | 4 | $118 |
| Myovant Sciences Inc. | 3 | $87 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $56 |
| Travere Therapeutics, Inc. | 3 | $55 |
| Hollister Incorporated | 2 | $48 |
| AstraZeneca | 2 | $43 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Clarus Therapeutics Inc. | 2 | $36 |
| Acerus Pharmaceuticals Corporation | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $23 |
| ABC Home Medical Supply, Inc. | 1 | $23 |
| Verity Pharmaceuticals Inc. | 1 | $22 |
| Blue Earth Diagnostics | 1 | $22 |
| Amgen | 1 | $19 |
| Progenics Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi | 1 | $15 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| Merck | 1 | $15 |
| Bayer | 1 | $15 |
| Urogen Pharma, Inc. | 1 | $14 |
How this compares
$3,594 in reported general payments places this provider in the 50th percentile of 878 urology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methenamine Hippurate | 14 | $1,350 |
| Tamsulosin Hcl | 27 | $325 |
| Finasteride | 14 | $183 |
Paid to pharmacies, not to this prescriber.
Other urology in Houston
- Arun RaiHouston$920K
- Donald GriffithHouston$732K
- Jonathan Clavell HernandezHouston$500K
- Ashish KamatHouston$481K
- Mohit KheraHouston$428K
- Ricardo GonzalezHouston$314K
- Richard LinkHouston$261K
- Steven CanfieldHouston$256K
- Run WangHouston$195K
- Kathleen KobashiHouston$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.